Burning Rock Biotech Limited
BNR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | 0.03 | -0.07 | -0.71 |
| FCF Yield | -19.37% | -37.65% | -32.18% | -10.96% |
| EV / EBITDA | -0.15 | -0.20 | -0.89 | -6.65 |
| Quality | ||||
| ROIC | -55.56% | -85.23% | -80.81% | -41.01% |
| Gross Margin | 70.26% | 67.59% | 67.47% | 71.70% |
| Cash Conversion Ratio | 0.27 | 0.39 | 0.47 | 0.60 |
| Growth | ||||
| Revenue 3-Year CAGR | -2.89% | 1.90% | 9.42% | 9.99% |
| Free Cash Flow Growth | 62.95% | 48.89% | 24.95% | -351.61% |
| Safety | ||||
| Net Debt / EBITDA | 1.73 | 1.16 | 1.00 | 1.80 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -518.92 |
| Efficiency | ||||
| Inventory Turnover | 2.85 | 2.52 | 1.41 | 1.17 |
| Cash Conversion Cycle | 170.35 | 208.37 | 268.46 | 268.73 |